An update on nanoformulations with FDA approved drugs for female reproductive cancer DOI

M. Thanga Raj,

Abha Meena, Richa Seth

и другие.

Journal of Microencapsulation, Год журнала: 2025, Номер unknown, С. 1 - 34

Опубликована: Март 20, 2025

Female reproductive cancers, including ovarian, cervical, breast, gestational trophoblastic and endometrial cancer, present significant challenges in therapy patient prognosis. Conventional chemotherapy often lacks selectivity, leading to systemic toxicity reduced treatment efficacy. Nanotechnology has emerged as a promising approach improve drug delivery therapeutic outcomes. Encapsulation of FDA-approved drugs within nanocarriers such liposomes, polymeric nanoparticles, lipid nanoparticles enables controlled release, reduces off-target effects, enhances accumulation at tumor sites. This targeted minimizes damage healthy tissues improves survival rates. Additionally, nanoformulations facilitate combination therapy, overcoming resistance maximizing Despite results, like scalability, reproducibility, regulatory approvals hinder widespread clinical applications. Developing personalized tailored individual profiles offers potential for precision cancer therapy. study explores the role enhancing treating female cancers.

Язык: Английский

Engineering magnetic nano-manipulators for boosting cancer immunotherapy DOI Creative Commons
Bin Yan, Siyao Wang, Chen Liu

и другие.

Journal of Nanobiotechnology, Год журнала: 2022, Номер 20(1)

Опубликована: Дек. 31, 2022

Abstract Cancer immunotherapy has shown promising therapeutic results in the clinic, albeit only a limited number of cancer types, and its efficacy remains less than satisfactory. Nanoparticle-based approaches have been to increase response immunotherapies address this limitation. In particular, magnetic nanoparticles (MNPs) as powerful manipulator are an appealing option for comprehensively regulating immune system vivo due their unique magnetically responsive properties high biocompatibility. This review focuses on assessing potential applications MNPs enhancing tumor accumulation immunotherapeutic agents immunogenicity, improving cell infiltration, creating immunotherapy-sensitive environment. We summarize recent progress application MNP-based manipulators augment immunotherapy, by multiple effects under different types external field. Furthermore, we highlight mechanisms underlying promotion antitumor immunity, including actuated delivery controlled release agents, tracking visualization real time, regulation innate/adaptive cells. Finally, consider perspectives challenges immunotherapy.

Язык: Английский

Процитировано

25

Polymer mechanochemistry in drug delivery: From controlled release to precise activation DOI
Zhiyuan Shi, Yong Hu, Xin Li

и другие.

Journal of Controlled Release, Год журнала: 2023, Номер 365, С. 259 - 273

Опубликована: Ноя. 24, 2023

Язык: Английский

Процитировано

14

Enhanced Anti-Tumor Effects of Natural Killer Cell-Derived Exosomes Through Doxorubicin Delivery to Hepatocellular Carcinoma Cells: Cytotoxicity and Apoptosis Study DOI Open Access
You Hee Choi, Ho Yong Kim, Jong‐Oh Park

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 2234 - 2234

Опубликована: Март 1, 2025

Exosomes are nanosized extracellular vesicles secreted by various cells, including natural killer (NK) and known for their low toxicity, high permeability, biocompatibility, strong targeting ability. NK cell-derived exosomes (NK-exos) contain cytotoxic proteins that enhance tumor-targeting efficiency, making them suitable treating solid tumors such as hepatocellular carcinoma (HCC). Despite potential in drug delivery, the mechanisms of drug-loaded NK-exos, particularly those loaded with doxorubicin (NK-exos-Dox), remain unclear HCC. This study explored anti-tumor effects NK-exos-Dox against Hep3B cells vitro. expressed exosome markers (CD9 CD63) (granzyme B perforin) measured 170-220 nm size. Compared to enhanced cytotoxicity apoptosis upregulating pro-apoptotic (Bax, cytochrome c, cleaved caspase 3, PARP) inhibiting anti-apoptotic protein (Bcl-2). These findings suggest significantly boost activating specific molecules, offering promising therapeutic opportunities tumor treatment,

Язык: Английский

Процитировано

0

Evaluation of Dual Drug Delivery Efficiency of Nanocomposite Hydrogel Containing Pectin for Combating Cancer DOI Open Access
Amos Luanda,

Manohar Mahadev,

R. Narayana Charyulu

и другие.

Polymers for Advanced Technologies, Год журнала: 2025, Номер 36(3)

Опубликована: Март 1, 2025

ABSTRACT Traditional chemotherapeutic approaches for cancer treatment often face challenges, such as limited bioavailability and efficacy of anticancer drugs due to a lack specificity quick metabolism. In this study, nanocomposite hydrogel, namely pectin‐ graft ‐poly(4‐acryloylmorpholine‐ co ‐2‐acrylamido‐2‐methyl‐1‐propanesulphonic acid) embedded with silver nanoparticles (Pec‐ g ‐poly(AcM‐ ‐AMPS)‐SNPs) was developed dual drug delivery system treatment. The the neat gel without (SNPs) were characterized using various techniques evaluated their efficiencies co‐delivery 5‐fluorouracil (5‐FU) doxorubicin (DOX) model drugs. exhibited pH‐responsive swelling behavior, comparatively higher observed nanocomposite, maximum at pH 7.4. process obeyed pseudo‐second‐order kinetic model. A similar observation made regarding release drugs, significantly About 83.9% 5‐FU 73.3% DOX released from 7.4 during 8 h. profile adhered first‐order Higuchi‐square root models. transport incorporated out matrix into dissolution medium be Fickian diffusion process. has been proven cytocompatible, demonstrated by cytotoxicity study carried MCF‐10A cells, suggesting its suitability oral combating cancer.

Язык: Английский

Процитировано

0

An update on nanoformulations with FDA approved drugs for female reproductive cancer DOI

M. Thanga Raj,

Abha Meena, Richa Seth

и другие.

Journal of Microencapsulation, Год журнала: 2025, Номер unknown, С. 1 - 34

Опубликована: Март 20, 2025

Female reproductive cancers, including ovarian, cervical, breast, gestational trophoblastic and endometrial cancer, present significant challenges in therapy patient prognosis. Conventional chemotherapy often lacks selectivity, leading to systemic toxicity reduced treatment efficacy. Nanotechnology has emerged as a promising approach improve drug delivery therapeutic outcomes. Encapsulation of FDA-approved drugs within nanocarriers such liposomes, polymeric nanoparticles, lipid nanoparticles enables controlled release, reduces off-target effects, enhances accumulation at tumor sites. This targeted minimizes damage healthy tissues improves survival rates. Additionally, nanoformulations facilitate combination therapy, overcoming resistance maximizing Despite results, like scalability, reproducibility, regulatory approvals hinder widespread clinical applications. Developing personalized tailored individual profiles offers potential for precision cancer therapy. study explores the role enhancing treating female cancers.

Язык: Английский

Процитировано

0